In September 2019, Beijing E-Town International Investment & Development Co invested 50 million yuan ($7.22 million) to increase the capital of Beijing Mabworks Biotech Co.

Registered in the Beijing Economic-Technological Development Area, Beijing Mabworks Biotech Co is a biopharmaceutical company in the clinical stage.

The company primarily researches and develops biomacromolecule drugs with commercially independent intellectual property rights. It is a domestic leader in monoclonal antibody drug development and industrialization technology capabilities and has formed a complete technical system.

At the beginning of 2020, the company completed a new round of financing that brought in nearly 1 billion yuan.

Website: http://www.mab-works.com/